Management of malignant phaeochromocytoma: A retrospective review of the use of MIBG and chemotherapy in the West Midlands

Clinical Oncology

Volumn 13, Issue 5, 2001, Pages 361-366

  Hartley, A ^a   Spooner, D ^a   Brunt, A M ^b  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b University Hospital of Staffordshire   (United Kingdom)

Author keywords

Chemotherapy; Malignant phaeochromocytoma; MIBG

Indexed keywords

(3 IODOBENZYL)GUANIDINE; (3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 131; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; ETOPOSIDE; FLUOROURACIL; IFOSFAMIDE; NAVELBINE; OCTREOTIDE; VINCRISTINE; YTTRIUM 90;

ADOLESCENT; ADULT; ARTICLE; CALCULATION; CHEMOTHERAPY; CLINICAL ARTICLE; DISEASE COURSE; DOSE RESPONSE; FEMALE; HORMONE RESPONSE; HUMAN; HYPERTENSION ENCEPHALOPATHY; ISOTOPE LABELING; MALE; MEDICAL RESEARCH; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZATION; RETROSPECTIVE STUDY; THROMBOCYTOPENIA;

EID: 0034764571     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1053/clon.2001.9290     Document Type: Article

References (26)

1. Bierwaltes WH, Sisson JC, Shapiro B, et al. Malignant potential of phaeochromocytoma: implications for follow up. Clin Res 1986;34:713A.
2. 131I MIBG: a comprehensive review of 116 reported patients. J Endocrinol Invest 1997;20:648-58.
3. Bestagno M, Pizzocaro C, Maira G, et al. Results of I-131 MIBG treatment in metastatic malignant phaeochromocytoma. J Nucl Biol Med 1991;35:277-9.
4. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981;47:207.
5. Shapiro B, Sisson JC, Wieland DM, et al. Radiopharmaceutical therapy with I-131 MIBG: results from ten years' experience. J Nucl Biol Med 1991;35:269-76.
6. Averbuch SD, Steakley CS, Young RC, et al. Malignant phaeochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine and dacarbazine. Ann Intern Med 1988;109:267-73.
7. Minami T, Doy Y, Tetsuo H, et al. Case of malignant phaeochromocytoma with successful control of systemic metastasis with CVD chemotherapy. J Jpn Soc Int Med 1996;85:2078-80.
8. Tada K, Okuda Y, Yamashita K. Three cases of malignant phaeochromocytoma treated with cyclophosphamide, vincristine and dacarbazine combination chemotherapy and alpha-methyl-p-tyrosine to control hypercatecholaminemia. Hormone Res 1998;49:295-7.
9. Noshiro T, Honma H, Shimizu K, et al. Two cases of malignant phaeochromocytoma treated with cyclophosphamide, vincristine and dacarbazine in a combined chemotherapy. Endocrine J 1996;43:279-84.
10. Siddiqui MZ, Von Eyben FE, Spanos G. High voltage irradiation and combination chemotherapy for malignant phaeochromocytoma. Cancer 1988;62:686-90.
11. Keiser HR, Goldstein DS, Wade JL, et al. Treatment of malignant phaeochromocytoma with combination chemotherapy. Hypertension 1985;7:118-24.
12. Mizuno O. A case of malignant phaeochromocytoma treated with a combination of cyclophosphamide, vincristine and dacarbazine(CVD). A review of the Japanese literature of malignant phaeochromocytoma treated with a combination of CVD [Eng abstr]. Nippon Naibunpi Gakkai Zasshi Folia Endocrinol Jpn 1994;70:1039-46.
13. Hatton MFQ, Reed N. Chemotherapy for neuroendocrine tumours: the Beatson Oncology Centre experience. Clin Oncol 1997;9:385-9.
14. Senen S, Reed NS, Connel J. Palliation of malignant phaeochromocytoma with combination chemotherapy. Eur J Cancer 1992;28:1006-7.
15. Srimuninnimit V, Wampler GL. Case report of metastatic familial phaeochromocytoma treated with cisplatin and 5-fluorouracil. Cancer Chemother Pharmacol 1991;28:217-9.
16. Sisson J, Shapiro B, Shulkin B, et al. Treatment of malignant phaeochromocytomas with I-131 metaiodobenzylguanidine and chemotherapy. Am J Clin Oncol 1999;22:364-70.
17. Shapiro B, Sisson JC, Eyre P, et al. I-131 MIBG a new agent in diagnosis and treatment of phaeochromocytoma. Cardiology 1985;72:137.
18. Beierwaltes WH. Update on basic research and clinical experience with metaiodobenzylguanidine. Med Pediatr Oncol 1987;15:163.
19. Gaze MN, Wheldon TE. Radiolabelled MIBG in the treatment of neuroblastoma. Eur J Cancer 1996;32A:93-6.
20. Wheldon TE, O'Donoghue JA, Barrett A, et al. The curability of tumours of different size by targeted radiotherapy using I-131 or Y-90. Radiother Oncol 1991;21:91-9.
21. Lewington V, Zivanovic M, Tristam M, et al. Radiolabelled metaiodobenzylguanidine targeted radiotherapy for malignant phaeochromocytoma. J Nucl Biol Med 1991;35:280-3.
22. Yax X, Wu C, Wu B. DNA content correlation with the prognosis of phaeochromocytoma [Eng abstr]. Chin J Surg 1997;35:176-7.
23. Yoshimoto T, Naruse M, Zeng Z, et al. The relative high frequency of p53 gene mutations in multiple and malignant phaeochromocytomas. J Endocrinol 1998;159:247-55.
24. Kubota Y, Nakada T, Sasagawa I, et al. Elevated levels of telomerase activity in malignant phaeochromocytoma. Cancer 1998;82:176-9.
25. Wu LT, Dicpinigaitis P, Bruckner H, et al. Hypertensive crises induced by treatment of malignant phaeochromocytoma with a combination of cyclophosphamide, vincristine and dacarbazine. Med Pediatr Oncol 1994;22:389-92.
26. Reed NS. Management of neuroendocrine tumours. Clin Oncol 1999;11:295-302.